Retrospective analysis of hepatitis B virus chronic infection in 247 patients: clinical stages, response to treatment and poor prognostic factors

[1]  V. Kim,et al.  Pegylated interferon alfa for chronic hepatitis B: systematic review and meta‐analysis , 2016, Journal of viral hepatitis.

[2]  N. Terrault,et al.  AASLD guidelines for treatment of chronic hepatitis B , 2016, Hepatology.

[3]  P. Lampertico,et al.  Optimal management of hepatitis B virus infection - EASL Special Conference. , 2015, Journal of hepatology.

[4]  R. Thimme,et al.  Antiviral Therapy in Hepatitis B Virus-Associated Liver Cirrhosis , 2015, Digestive Diseases.

[5]  Jung-Hwan Yoon,et al.  Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients , 2015, PloS one.

[6]  F. Farinati,et al.  Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease. , 2015, World journal of hepatology.

[7]  M. Deutsch,et al.  The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management , 2015, Annals of gastroenterology.

[8]  Daniel S. Berman,et al.  Is Metabolic Syndrome Predictive of Prevalence, Extent, and Risk of Coronary Artery Disease beyond Its Components? Results from the Multinational Coronary CT Angiography Evaluation for Clinical Outcome: An International Multicenter Registry (CONFIRM) , 2015, PloS one.

[9]  M. Buti,et al.  Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. , 2015, Journal of hepatology.

[10]  R. Thimme,et al.  Natural history of chronic hepatitis B virus infection , 2015, Medical Microbiology and Immunology.

[11]  G. Raimondo,et al.  Hepatitis B virus and hepatitis C virus dual infection. , 2014, World journal of gastroenterology.

[12]  J. Jang,et al.  Update on hepatitis B virus infection. , 2014, World journal of gastroenterology.

[13]  Y. Seo,et al.  Short- and long-term outcome of interferon therapy for chronic hepatitis B infection. , 2014, World journal of gastroenterology.

[14]  J. Chen,et al.  Association of Hepatitis B Virus Mutations of A1846T and C1913A/G With Acute-on-Chronic Liver Failure Development From Different Underlying Chronic Liver Diseases , 2013, Hepatitis monthly.

[15]  Sheng-Nan Lu,et al.  Prediction models of long‐term Cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: Risk scores integrating host and virus profiles , 2013, Hepatology.

[16]  R. Fontana,et al.  Meta‐analysis: the impact of oral anti‐viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B , 2013, Alimentary pharmacology & therapeutics.

[17]  Yoshiyuki Suzuki,et al.  Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection , 2013, Hepatology.

[18]  G. Dusheiko.  Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[19]  Shigui Yang,et al.  Serolological Profile Among HBsAg-Positive Infections in Southeast China: A Community-Based Study , 2013, Hepatitis monthly.

[20]  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. , 2012, Journal of hepatology.

[21]  Chien-Jen Chen,et al.  Natural history of chronic hepatitis B REVEALed , 2011, Journal of gastroenterology and hepatology.

[22]  F. Souto,et al.  Clinical profile of hepatitis B virus chronic infection in patients of Brazilian liver reference units , 2010, Hepatology international.

[23]  G. Lau.  Current treatments for patients with HBeAg‐positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[24]  K. Tsoi,et al.  Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma , 2008, Alimentary pharmacology & therapeutics.

[25]  B. Bacon.  Assessing evidence from clinical trials in chronic hepatitis C , 2006, Journal of viral hepatitis.

[26]  G. Gerken,et al.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.

[27]  G. Colucci,et al.  Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. , 2003, Journal of hepatology.

[28]  L. Seeff,et al.  Natural history of chronic hepatitis C , 2002, Hepatology.

[29]  Chien-Jen Chen,et al.  Hepatitis B e antigen and the risk of hepatocellular carcinoma. , 2002, The New England journal of medicine.

[30]  M. Buti,et al.  Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. , 1999, Hepatology.

[31]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.